Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 274693-27-5
Drug Levels and Effects
Summary of Use during Lactation
No published information is available on the use of ticagrelor during breastfeeding. Because ticagrelor and its active metabolite are more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. If it is used by a nursing mother, monitor the infant for bruising and bleeding.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Substance Identification
Substance Name
Ticagrelor
CAS Registry Number
274693-27-5
Drug Class
- Breastfeeding
- Lactation
- Purinergic P2Y Receptor Antagonists
- Platelet Aggregation Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI-MS(n), NMR and their synthesis.[J Pharm Biomed Anal. 2016]Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI-MS(n), NMR and their synthesis.Kumar N, Devineni SR, Gajjala PR, Gupta DK, Bhat S, Kumar R, Dubey SK, Kumar P. J Pharm Biomed Anal. 2016 Feb 20; 120:248-60. Epub 2015 Dec 24.
- Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.[Drug Metab Dispos. 2010]Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.Teng R, Oliver S, Hayes MA, Butler K. Drug Metab Dispos. 2010 Sep; 38(9):1514-21. Epub 2010 Jun 15.
- Review Everolimus.[Drugs and Lactation Database (...]Review Everolimus.. Drugs and Lactation Database (LactMed®). 2006
- Review Lovastatin.[Drugs and Lactation Database (...]Review Lovastatin.. Drugs and Lactation Database (LactMed®). 2006
- Review Pitavastatin.[Drugs and Lactation Database (...]Review Pitavastatin.. Drugs and Lactation Database (LactMed®). 2006
- Ticagrelor - Drugs and Lactation Database (LactMed®)Ticagrelor - Drugs and Lactation Database (LactMed®)
- Protein Links for Nucleotide (Select 2314036769) (2)Protein
- hypothetical protein W97_02517 [Coniosporium apollinis CBS 100218]hypothetical protein W97_02517 [Coniosporium apollinis CBS 100218]gi|494826178|gb|EON63290.1||gnl|WGS |W97_02517T0Protein
Your browsing activity is empty.
Activity recording is turned off.
See more...